Roche Reports real-world evidence Data for Asundexian in Type 2 diabetes

Roche today announced real-world evidence results for Asundexian in patients with Type 2 diabetes. The study demonstrated that Asundexian demonstrates favorable safety profile compared to standard of care or placebo. These results provide important insights into the treatment of Type 2 diabetes and support the continued development of Asundexian in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Asundexian was consistent with previous observations, with no new safety signals identified.